



[www.genfit.com](http://www.genfit.com)

## GENFIT: NEW PRIVATE PLACEMENT AS PART OF ITS EQUITY FINANCING AGREEMENT WITH YORKVILLE

**Lille (France), Cambridge (Massachusetts, United States), November 4, 2011** – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces a €93,500 private placement to YA Global Master SPV Ltd, a fund managed by Yorkville Advisors LLC.

This second capital increase operation finalized on November 4, 2011 follows the delegations granted to the Management Board by the third and fourth resolutions adopted by the Extraordinary General Meeting held on September 28, 2011.

As announced in the Company's press release of August 24, 2011 and in accordance with the agreement signed with Yorkville, these new shares have been subscribed to compensate a one-time commitment fee due by GENFIT to YA GLOBAL.

Shareholders' equity is reinforced by the issuance of 50,000 new Company shares. These shares will have the same rights than the existing ones. The post-operation Company's share capital will be made of 13,630,678 shares.

### About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI, SERVIER, ...), to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). [www.genfit.com](http://www.genfit.com)

### Contacts:

#### GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board  
+33 (0)3 2016 4000

#### MILESTONES – Press Relations

Bruno Arabian  
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – [barabian@milestones.fr](mailto:barabian@milestones.fr)